OCULAR THERAPEUTIX IN

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

04 Mar 2024 08:45:09 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

01 Mar 2024 11:02:47 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

26 Feb 2024 08:47:12 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

23 Feb 2024 09:33:55 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

22 Feb 2024 08:45:24 By NetDania Notify

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

22 Feb 2024 06:32:00 By Nasdaq GlobeNewswire

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

22 Feb 2024 06:31:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

22 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

15 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

13 Feb 2024 06:38:24 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

25 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

18 Dec 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

13 Dec 2023 21:09:58 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

13 Dec 2023 15:01:11 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

08 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

07 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results

24 Oct 2023 07:00:01 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

03 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

06 Sep 2023 07:01:11 By Nasdaq GlobeNewswire